中国医学装备
中國醫學裝備
중국의학장비
CHINA MEDICAL EQUIPMENT
2014年
7期
99-101,102
,共4页
肺癌%化疗%贝伐单抗%血管内皮生长因子
肺癌%化療%貝伐單抗%血管內皮生長因子
폐암%화료%패벌단항%혈관내피생장인자
Lung cancer%Chemotherapy%Bevacizumab%Vascular endothelial growth factor
目的：研究贝伐单抗联合培美曲塞+顺铂化疗方案在肺癌中的应用价值。方法：将240例进展期非小细胞肺癌患者随机分为给予贝伐单抗联合培美曲塞＋顺铂化疗的观察组和给予培美曲塞＋顺铂化疗的对照组，观察化疗后近期疗效指标、肿瘤内分泌指标以及远期疗效指标。结果：①观察组患者的整体缓解情况优于对照组，客观有效率和疾病控制率均高于对照组，其差异有统计学意义(x2=8.382，x2=5.992；P＜0.05)；②治疗后，两组患者的血管内皮生长因子VEGF-A、VEGF-B、VEGF-C水平均低于治疗前，且观察组患者的VEGF-A、VEGF-B和VEGF-C水平低于对照组，其差异有统计学意义(t=6.263，t=6.094，t=5.892；P＜0.05)；③观察组患者的1年、3年、5年生存率高于对照组，其差异有统计学意义(x2=6.883，x2=7.273， x2=6.274，P＜0.05)。无进展生存时间、总生存时间均高于对照组，其差异有统计学意义(t=9.752，t=7.883；P＜0.05)。结论：贝伐单抗联合培美曲塞+顺铂化疗方案有助于促进肿瘤缓解、降低VEGF水平、抑制肿瘤血管新生及延长整体生存时间，具有积极的临床价值。
目的：研究貝伐單抗聯閤培美麯塞+順鉑化療方案在肺癌中的應用價值。方法：將240例進展期非小細胞肺癌患者隨機分為給予貝伐單抗聯閤培美麯塞＋順鉑化療的觀察組和給予培美麯塞＋順鉑化療的對照組，觀察化療後近期療效指標、腫瘤內分泌指標以及遠期療效指標。結果：①觀察組患者的整體緩解情況優于對照組，客觀有效率和疾病控製率均高于對照組，其差異有統計學意義(x2=8.382，x2=5.992；P＜0.05)；②治療後，兩組患者的血管內皮生長因子VEGF-A、VEGF-B、VEGF-C水平均低于治療前，且觀察組患者的VEGF-A、VEGF-B和VEGF-C水平低于對照組，其差異有統計學意義(t=6.263，t=6.094，t=5.892；P＜0.05)；③觀察組患者的1年、3年、5年生存率高于對照組，其差異有統計學意義(x2=6.883，x2=7.273， x2=6.274，P＜0.05)。無進展生存時間、總生存時間均高于對照組，其差異有統計學意義(t=9.752，t=7.883；P＜0.05)。結論：貝伐單抗聯閤培美麯塞+順鉑化療方案有助于促進腫瘤緩解、降低VEGF水平、抑製腫瘤血管新生及延長整體生存時間，具有積極的臨床價值。
목적：연구패벌단항연합배미곡새+순박화료방안재폐암중적응용개치。방법：장240례진전기비소세포폐암환자수궤분위급여패벌단항연합배미곡새＋순박화료적관찰조화급여배미곡새＋순박화료적대조조，관찰화료후근기료효지표、종류내분비지표이급원기료효지표。결과：①관찰조환자적정체완해정황우우대조조，객관유효솔화질병공제솔균고우대조조，기차이유통계학의의(x2=8.382，x2=5.992；P＜0.05)；②치료후，량조환자적혈관내피생장인자VEGF-A、VEGF-B、VEGF-C수평균저우치료전，차관찰조환자적VEGF-A、VEGF-B화VEGF-C수평저우대조조，기차이유통계학의의(t=6.263，t=6.094，t=5.892；P＜0.05)；③관찰조환자적1년、3년、5년생존솔고우대조조，기차이유통계학의의(x2=6.883，x2=7.273， x2=6.274，P＜0.05)。무진전생존시간、총생존시간균고우대조조，기차이유통계학의의(t=9.752，t=7.883；P＜0.05)。결론：패벌단항연합배미곡새+순박화료방안유조우촉진종류완해、강저VEGF수평、억제종류혈관신생급연장정체생존시간，구유적겁적림상개치。
Objective: To study the application value of bevacizumab combined with pemetrexed + pluscisplatin first-line chemotherapy in treating lung cancer. Methods: Advanced non small cell lung cancer patients from January 2011 to December 2012 were enrolled and randomly divided into observation group given bevacizumab combined with pemetrexed + pluscisplatin and control group given pemetrexed +pluscisplatin. Then long-term therapeutic effect index, tumor endocrine index and long-term therapeutic effect index were observed. Results:(1)overall remission condition of observation group were better than those of control group(u=6.782, P<0.05), objective response rate(x2=8.382, P<0.05) and disease control rate(x2=5.992, P<0.05) of observation group were higher than those of control group,the difference was statistically significant(P<0.05);(2)after chemotherapy, VEGF-A, VEGF-B and VEGF-C levels of two groups were lower than those before chemotherapy and VEGF-A(t=6.263, P<0.05), VEGF-B(t=6.094, P<0.05) and VEGF-C(t=5.892, P<0.05) levels of observation group were lower than those of control group, the difference was statistically significant(P<0.05);(3)1 year(x2=6.883, P<0.05), 3 year(x2=7.273, P<0.05) and 5 year(x2=6.274, P<0.05) survival rate and progression free survival(t=9.752, P<0.05), overall survival time(t=7.883, P<0.05) of observation group were higher than those of control group, the difference was statistically significant(P<0.05). Conclusion: Bevacizumab combined with pemetrexed+pluscisplatin have positive clinical value for it is helpful to improve the remission, decreased the level of vascular endothelial growth factor, inhibit tumor angiogenesis, prolonged overall survival time.
